000125372 001__ 125372
000125372 005__ 20240228145525.0
000125372 0247_ $$2doi$$a10.1200/JCO.2017.73.0242
000125372 0247_ $$2pmid$$apmid:28640698
000125372 0247_ $$2ISSN$$a0732-183X
000125372 0247_ $$2ISSN$$a1527-7755
000125372 0247_ $$2altmetric$$aaltmetric:21321235
000125372 037__ $$aDKFZ-2017-01505
000125372 041__ $$aeng
000125372 082__ $$a050
000125372 1001_ $$0P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aSturm, Dominik$$b0$$eFirst author$$udkfz
000125372 245__ $$aPediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management.
000125372 260__ $$aAlexandria, Va.$$bAmerican Society of Clinical Oncology$$c2017
000125372 3367_ $$2DRIVER$$aarticle
000125372 3367_ $$2DataCite$$aOutput Types/Journal article
000125372 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1661239181_8349$$xReview Article
000125372 3367_ $$2BibTeX$$aARTICLE
000125372 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000125372 3367_ $$00$$2EndNote$$aJournal Article
000125372 520__ $$aGliomas are the most common CNS tumors in children and adolescents, and they show an extremely broad range of clinical behavior. The majority of pediatric gliomas present as benign, slow-growing lesions classified as grade I or II by the WHO classification of CNS tumors. These pediatric low-grade gliomas (LGGs) are fundamentally different from IDH-mutant LGGs occurring in adults, because they rarely undergo malignant transformation and show excellent overall survival under current treatment strategies. However, a significant fraction of gliomas develop over a short period of time and progress rapidly and are therefore classified as WHO grade III or IV high-grade gliomas (HGGs). Despite all therapeutic efforts, they remain largely incurable, with the most aggressive forms being lethal within months. Thus, the intentions of neurosurgeons, pediatric oncologists, and radiotherapists to improve care for pediatric patients with glioma range from increasing quality of life and preventing long-term sequelae in what is often a chronic, but rarely life-threatening disease (LGG), to uncovering effective treatment options to prolong patient survival in an almost universally fatal setting (HGG). The last decade has seen unprecedented progress in understanding the molecular biology underlying pediatric gliomas, fueling hopes to achieve both goals. Large-scale collaborative studies around the globe have cataloged genomic and epigenomic alterations in gliomas across ages, grades, and histologies. These studies have revealed biologic subgroups characterized by distinct molecular, pathologic, and clinical features, with clear relevance for patient management. In this review, we summarize hallmark discoveries that have expanded our knowledge in pediatric LGGs and HGGs, explain their role in tumor biology, and convey our current concepts on how these findings may be translated into novel therapeutic approaches.
000125372 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000125372 588__ $$aDataset connected to CrossRef, PubMed,
000125372 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b1$$udkfz
000125372 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David$$b2$$eLast author$$udkfz
000125372 773__ $$0PERI:(DE-600)2005181-5$$a10.1200/JCO.2017.73.0242$$gVol. 35, no. 21, p. 2370 - 2377$$n21$$p2370 - 2377$$tJournal of clinical oncology$$v35$$x1527-7755$$y2017
000125372 909CO $$ooai:inrepo02.dkfz.de:125372$$pVDB
000125372 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000125372 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000125372 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000125372 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000125372 9141_ $$y2017
000125372 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000125372 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CLIN ONCOL : 2015
000125372 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000125372 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000125372 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000125372 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000125372 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000125372 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000125372 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000125372 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000125372 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000125372 915__ $$0StatID:(DE-HGF)9920$$2StatID$$aIF >= 20$$bJ CLIN ONCOL : 2015
000125372 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000125372 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x1
000125372 980__ $$ajournal
000125372 980__ $$aVDB
000125372 980__ $$aI:(DE-He78)B062-20160331
000125372 980__ $$aI:(DE-He78)L101-20160331
000125372 980__ $$aUNRESTRICTED